MedTrace Logo

Evaluation of the Efficacy and Safety of the Dermal Filler for Augmentation of Labia Majora.

NCT04652817 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2020-12-03

No results posted yet for this study

Summary

The study is an open-label uncontrolled single-center study for the evaluation of the Performance characteristics (efficacy and safety) of the dermal filler "MMI-22-04-2019" on the female genital area for the aesthetic, medicinal, functional and reconstructive indications.

Conditions

  • Labia Majora Atrophy and Hypotrophy

Interventions

DEVICE

MMI-22-04-2019

A cross-linked form of the Hyaluronic Acid is used in intradermal injection to augment the labia majora area.

Sponsors & Collaborators

  • Mesoestetic Pharma Group S.L.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-11
Primary Completion
2020-07-12
Completion
2020-08-26

Countries

  • Bulgaria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04652817 on ClinicalTrials.gov